A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Study ID
NCT02791334

Study type
Interventional

Study phase
Phase 1

Study status
Active, not recruiting

Trial Acronym

PACT

Trial Summary

The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.

More informations

Trial Starting Date

Jun 29,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

215